| Product Code: ETC7636000 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Oncology-Cancer Drugs Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Oncology-Cancer Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Oncology-Cancer Drugs Market - Industry Life Cycle |
3.4 Ireland Oncology-Cancer Drugs Market - Porter's Five Forces |
3.5 Ireland Oncology-Cancer Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Ireland Oncology-Cancer Drugs Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Ireland Oncology-Cancer Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Ireland |
4.2.2 Technological advancements in oncology-cancer drugs |
4.2.3 Rising healthcare expenditure and government initiatives to improve cancer care |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval |
4.3.2 High costs associated with oncology-cancer drugs |
4.3.3 Limited reimbursement policies for expensive cancer treatments |
5 Ireland Oncology-Cancer Drugs Market Trends |
6 Ireland Oncology-Cancer Drugs Market, By Types |
6.1 Ireland Oncology-Cancer Drugs Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Chemotherapy, 2021- 2031F |
6.1.4 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Targeted Therapy, 2021- 2031F |
6.1.5 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Immunotherapy (Biologic Therapy), 2021- 2031F |
6.1.6 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Hormonal Therapy, 2021- 2031F |
6.2 Ireland Oncology-Cancer Drugs Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Lung Cancer, 2021- 2031F |
6.2.3 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Stomach Cancer, 2021- 2031F |
6.2.4 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Colorectal Cancer, 2021- 2031F |
6.2.5 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.2.6 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Prostate Cancer, 2021- 2031F |
6.2.7 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Liver Cancer, 2021- 2031F |
6.2.8 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Other Cancers, 2021- 2031F |
6.2.9 Ireland Oncology-Cancer Drugs Market Revenues & Volume, By Other Cancers, 2021- 2031F |
7 Ireland Oncology-Cancer Drugs Market Import-Export Trade Statistics |
7.1 Ireland Oncology-Cancer Drugs Market Export to Major Countries |
7.2 Ireland Oncology-Cancer Drugs Market Imports from Major Countries |
8 Ireland Oncology-Cancer Drugs Market Key Performance Indicators |
8.1 Patient survival rates |
8.2 Adoption rate of innovative cancer therapies |
8.3 Rate of clinical trial participation in oncology-cancer drugs |
9 Ireland Oncology-Cancer Drugs Market - Opportunity Assessment |
9.1 Ireland Oncology-Cancer Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Ireland Oncology-Cancer Drugs Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 Ireland Oncology-Cancer Drugs Market - Competitive Landscape |
10.1 Ireland Oncology-Cancer Drugs Market Revenue Share, By Companies, 2024 |
10.2 Ireland Oncology-Cancer Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here